Laufende Studien

ROSETTA Breast-01
fortgeschritten/metastasiert
triple negatives PD-L1 negatives
Mammakarzinom
Phase III

A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

INAVO123
fortgeschritten/metastasiert
HR+/HER2- PIK3CA+
Mammakarzinom
Phase III

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (INAVO123)

ASCENT-05
post-neoadjuvant
triple negatives Mammakarzinom
Phase III

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

GeparPiPPa
neoadjuvant
HER2+/HR+/PIK3CA mutiertes Mammakarzinom
Phase II

A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer

ERIKA/ABCSG 63
neoadjuvant
HR+ / HER2- Mammakarzinom
Phase II

Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer

TroFuse-032
neoadjuvant
triple negatives oder HR low+/HER2-
high-risk Mammakarzinom
Phase III

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Sigvie-003
Stadium IIIB, IIIC, IV NSCLC
PD-L1 TC ≥50%
1^st line Therapie
Phase III

An open-label, randomized, controlled phase 3 study of sigvotatug vedotin in combination with pembrolizumab compared with pembrolizumab monotherapy as first-line treatment in participants with PD-L1 high (≥50% of tumor cells expressing PD-L1), locally advanced, unresectable, or metastatic non-small cell lung cancer

PADL1NK-005
Stadium IIIB, IIIC, IV NSCLC
PD-L1 TPS≥1%
Vorbehandelte Patienten (2L+)
Phase III

A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

BRUIN-CLL-211
r/r CLL/SLL
1-3 Vortherapien inklusive cBTKi
Phase II

A Phase 2, Open-label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refactory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

BGB-16673-302
r/r CLL/SLL
>1 Vortherapie inklusive
cBTKi, BCL2i und ncBTKi
Phase III

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

BELLWAVE-011
CLL/SLL
1^st line Therapie
Phase III

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CLL 16
Hochrisiko CLL
1^st line Therapie
Phase III

A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) Compared to Obinutuzumab and Venetoclax (GVE) in Previously Untreated Patients With High Risk (17P-deletion, TP53-mutation or Complex Karyotype) Chronic Lymphatic Leukemia (CLL)

SYBIL
palliativ
HER2+ Mammakarzinom
Beobachtungs-/Diagnostikstudie

SIBYL: obServation of therapy response with lIquid BiopsY evaLuation